Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660000 | PMC |
| http://dx.doi.org/10.3324/haematol.2012.082271 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation.
Front Immunol
December 2024
Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
Article Synopsis
- * Allogeneic hematopoietic stem cell transplant (allo-HCT) is the sole curative immunotherapy for certain blood cancers, but using ICIs before or after allo-HCT can lead to increased risks of severe complications such as graft-versus-host disease.
- * Ongoing research targets the challenge of combining ICIs with allo-HCT to maximize benefits while reducing side effects, emphasizing a need for better strategies in utilizing these immunotherapies for blood malignancies. *
Chemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow.
Blood Adv
January 2025
Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
In allogeneic hematopoietic stem cell transplantation (allo-SCT), alloreactive donor T cells mediate the graft-versus-leukemia effect but also attack nonhematopoietic tissues, causing graft-versus-host disease (GVHD). Reducing alloreactive T-cell trafficking to GVHD target tissues while allowing their access to bone marrow (BM) and spleen, major sites of malignant hematopoiesis, is a rational strategy for reducing the GVHD risk when using alloreactive T cells as a therapeutic. Here, we show that effector T-cell (Teff) entry into BM and spleen in unmanipulated mice and in mice that received transplantation without alloreactive T cells is augmented by pertussis toxin (PTX)-sensitive chemokine receptor signaling.
View Article and Find Full Text PDFAnti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model.
Arthritis Res Ther
May 2024
Department of Dermatology, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, 910-1193, Japan.
Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular injury and inflammation, followed by excessive fibrosis of the skin and other internal organs, including the lungs. CX3CL1 (fractalkine), a chemokine expressed on endothelial cells, supports the migration of macrophages and T cells that express its specific receptor CX3CR1 into targeted tissues. We previously reported that anti-CX3CL1 monoclonal antibody (mAb) treatment significantly inhibited transforming growth factor (TGF)-β1-induced expression of type I collagen and fibronectin 1 in human dermal fibroblasts.
View Article and Find Full Text PDFKinetics of Recovery of Naïve and Memory T Cells in Acute Leukemia Patients after Allogeneic Stem Cell Transplantation Depending on Different GVHD Prophylaxis Regimens.
Int J Hematol Oncol Stem Cell Res
January 2024
Department of BMT, Immunotherapy and Post-BMT Complications Department, National Research Center for Hematology, Moscow, Russian Federation.
Memory T cells are a heterogeneous population of immune cells that provide adaptive immunity. Its full recovery seems essential for graft-versus-tumor reactions that provide an opportunity for biological cure in patients with acute leukemia. The use of mismatched or haploidentical donors has increased, which has become possible because of modifications in graft versus host disease (GVHD) prophylaxis.
View Article and Find Full Text PDFSuccessful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline -mutated acute myeloid leukemia.
Heliyon
January 2024
Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background: Acute graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with significant morbidity and mortality, and efficacy of currently available therapeutics are limited. Acute and chronic GVHD are similar in that both are initiated by antigen presenting cells and activation of alloreactive B-cells and T-cells, subsequently leading to inflammation, tissue damage, and organ failure. One difference is that acute GVHD is mostly attributed to T-cell activation and cytokine release, whereas B-cells are the key players in chronic GVHD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!